Latest Distribution Partnerships News

Control Bionics Limited has announced a $2.06 million non-renounceable rights issue to fund the commercial expansion of its NeuroStrip device and bolster NeuroNode operations. The capital raise is underwritten to approximately $1.15 million by major shareholders and strategic partners.

Biome Australia has secured key distribution partnerships with Mecca and Go Vita, launching its Activated Probiotics range into premium beauty and health food channels across Australia.

BNK Banking Corporation reported a strong FY25 performance, driven by margin expansion and strategic transactions that doubled non-interest income. The bank’s capital position strengthened significantly, setting the stage for future growth.

Sprintex Limited reported a 26% revenue increase for FY25 but also a 37% rise in net loss, as it accelerates global expansion through key distribution deals and manufacturing upgrades.

MyEco Group Ltd reported an 8.6% revenue increase to $15.7 million in FY25, driven by strong growth in its MyEco® branded products and improved margins. The company cut its net loss by nearly half, supported by operational restructuring and expanding market presence.

Genetic Signatures Limited reported a 63% revenue surge to $15.9 million in FY25, driven by strong Australian sales and progress in EMEA, while navigating a $20.1 million net loss and a strategic pivot towards partnerships for automated diagnostics.

Medical Developments International Ltd reported an 18% increase in revenue to $39.1 million for FY25, returning to profitability with a net profit after tax of $0.1 million. The company advanced its Penthrox market expansion through regulatory approvals and new partnerships.

SportsHero Limited reveals key details of its exclusive distribution deal with Yes2Games, targeting mobile game markets in Indonesia, the Philippines, Thailand, and Malaysia, though revenue impact remains pending.

AML3D has appointed German firm DMFG Solutions as a second European distributor, complementing its recent UK partnership and supporting a AU$5 million investment in a new technology centre.

Vitrafy Life Sciences reported a $32.7 million loss for FY25, driven by investments in its next-generation cryopreservation platform following a $35 million IPO and a $4.8 million government grant. The company is progressing commercialization efforts with key partnerships in human and animal health.

TasFoods reported a 19.9% revenue decline in Q2 2025 amid persistent poultry oversupply and discounted prices in Tasmania, while advancing strategic initiatives to stabilize operations and improve shareholder returns.

EVE Health Group has completed its acquisition of Nextract, raised $1 million to fund manufacturing, and achieved key regulatory and commercial milestones for its pharmaceutical products targeting erectile dysfunction and dysmenorrhea.